Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
In the landscape of head and neck cancers, few tumors possess the paradoxical nature of Adenoid Cystic Carcinoma (AdCC) of the salivary glands. It is a study in contradictions: often slow-growing and deceptively indolent, yet relentlessly invasive with a grim…
In the shadowy world of pancreatic cancer, one name casts a long, dark shadow: pancreatic ductal adenocarcinoma (PDAC). It is the notorious aggressor, the silent killer whose reputation is well-earned. Yet, lurking in the periphery is a far more enigmatic…
For a patient diagnosed with pancreatic acinar cell carcinoma (ACC), the successful surgical removal of the tumor—a Whipple procedure or a distal pancreatectomy—is a monumental victory. It is a moment of immense relief, a tangible step towards a cure. Yet,…
The pancreas, a deep-seated and unassuming organ, is a marvel of biological engineering. It functions as a dual-purpose factory: its endocrine cells meticulously calibrate blood sugar with insulin and glucagon, while its exocrine cells produce a potent cocktail of digestive…
Pancreatic Ductal Adenocarcinoma (PDAC) is often described as an “intractable” disease, a term that speaks to its profound resistance to treatment. But this label, while accurate, is incomplete. It paints a picture of a homogenous, indestructible enemy. A more novel…
In the grim lexicon of pancreatic cancer, one term casts a long, dark shadow: Pancreatic Ductal Adenocarcinoma (PDAC). It is the relentless juggernaut, the silent killer that dominates over 90% of diagnoses and dictates the narrative of despair. Lurking in…
Diagnosing pancreatic acinar cell carcinoma (ACC) is less a linear clinical pathway and more a complex detective story. The initial clues are often frustratingly vague—abdominal pain, weight loss, or occasionally, a distinctive paraneoplastic syndrome characterized by polyarthralgia and eosinophilia due…
The prognosis for pancreatic acinar cell carcinoma (ACC) has long been viewed through a grim, monolithic lens, often conflated with its notoriously aggressive cousin, pancreatic ductal adenocarcinoma (PDAC). Traditional statistics, citing a five-year survival rate hovering between 25-50% for resectable…
To ask for the “best” treatment for pancreatic acinar cell carcinoma (ACC) is to pose a question with a moving target. In the world of oncology, “best” is rarely a single, universally applicable protocol, but for a rare and enigmatic…
When we speak of pancreatic cancer, the mind often conjures a grim, well-defined portrait: painless jaundice, a silent killer discovered too late. This narrative, while tragically accurate for the more common pancreatic ductal adenocarcinoma (PDAC), dangerously obscures the unique and…
